Abstract
The major contemporary bioterrorist event which has opened up programs of
research and development (R&D) in pharmaceutical countermeasures and
treatments was the anthrax mail attacks which occurred only weeks after the
9/11 atrocities, in October 2001. The mailings killed five people and exposed
hundreds more - with thousands of US citizens seeking prophylactic
antibiotics. Since then the biodefense industry has grown massively, with the
US releasing around $50bn in biodefense funding in 2001-2009. Other
international bodies, such as the EU, have also increased their vigilance and
research efforts. This report sets out to describe and analyze the work of the
biodefense industry in terms of past, present and future pharmaceutical
research, development and production to counter or treat diseases caused by
biological attack. It also describes government policies and initiatives in
several countries which have spurred research and production in pharmaceutical
countermeasures and treatments for such diseases and will examine the various
factors which influence those policies and the market, including current and
future threats and how the industry is responding to new discoveries.
| 
View Cart
